USADA notifies UFC of a possible in competition failure by Jon Jones

USADA notifies UFC of a possible in competition failure by Jon Jones

Jones tested positive for Turinabol, the same drug that USADA flagged Frank Mir for per TMZ.

You can’t make this up. Jon Jones is once again in hot water as it pertains to drug testing.  USADA notified the UFC of a potential failed in competition test for UFC 214. TMZ reported he was flagged for Turinabol, an anabolic steroid and could face a four year suspension at this point. It’s an unbelievable development in the saga of one of the most storied UFC careers.

TMZ Sports was the first outlet to break the news, but it has since been confirmed by various trusted media outlets. The UFC, Jon Jones and Daniel Cormier all were recently informed but we’ve yet to hear from Jones or Cormier.  It would seem any fight with Jones and Brock Lesnar at this point, would have to take place within the WWE ring.

The UFC issued a statement which can be read below in its entirety.

The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) has informed Jon Jones of a potential Anti-Doping Policy violation stemming from an in-competition sample collected following his weigh-in on July 28, 2017.

USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case involving Jones, as it relates to the UFC Anti-Doping Policy and future UFC participation. Under the UFC Anti-Doping Policy, there is a full and fair legal process that is afforded to all athletes before any sanctions are imposed. The California State Athletic Commission (CSAC) also retains jurisdiction over this matter as the sample collection was performed the day before Jones’ bout at UFC 214 in Anaheim, CA, and USADA will work to ensure that the CSAC has the necessary information to determine its proper judgment of Jones’ potential anti-doping violation.

Additional information will be provided at the appropriate time as the process moves forward.

We’ll provide further information as it becomes available.